Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Autor: Grossman SA; Johns Hopkins University, Baltimore, Maryland., Romo CG; Johns Hopkins University, Baltimore, Maryland., Rudek MA; Johns Hopkins University, Baltimore, Maryland., Supko J; Massachusetts General Hospital, Boston, Massachusetts., Fisher J; Johns Hopkins University, Baltimore, Maryland., Nabors LB; University of Alabama Birmingham, Birmingham, Alabama., Wen PY; Dana-Farber Cancer Institute, Boston, Massachusetts., Peereboom DM; Cleveland Clinic, Cleveland, Ohio., Ellingson BM; University of California Los Angeles, Los Angeles, California., Elmquist W; University of Minnesota, Minneapolis, Minnesota., Barker FG; Massachusetts General Hospital, Boston, Massachusetts., Kamson D; Johns Hopkins University, Baltimore, Maryland., Sarkaria JN; Mayo Clinic, Rochester, Minnesota., Timmer W; National Cancer Institute, Bethesda, Maryland., Bindra RS; Yale University, New Haven, Connecticut., Ye X; Johns Hopkins University, Baltimore, Maryland.
Jazyk: angličtina
Zdroj: Neuro-oncology [Neuro Oncol] 2020 Oct 14; Vol. 22 (10), pp. 1422-1424.
DOI: 10.1093/neuonc/noaa142
Databáze: MEDLINE